New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
09:19 EDTAGN, VRXValeant's raised Allergan bid may not be enough, says Wells Fargo
Wells Fargo believes Valeant's (VRX) new offer for Allergan (AGN), which includes $10 more per share in cash and a $25 per share contingent value right for DARPin, may still be insufficient for Allergan. Wells notes that based on Valeant's last closing price, the total new offer for Allergan is around $166 per share. Shares of Allergan are down $1.03 to $163.99 in pre-market trading while Valeant shares are down 99c to $128.96.
News For AGN;VRX From The Last 14 Days
Check below for free stories on AGN;VRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
09:07 EDTVRX, AGNAllergan filed answer in federal court reponding to Valeant, Pershing claims
Subscribe for More Information
08:05 EDTAGNAllergan says Ozurdex apporved in EU for treatment of diabetic macular edema
Subscribe for More Information
August 27, 2014
13:33 EDTVRX, AGNValeant, Pershing suit against Allergan expedited, WSJ says
After a hearing on Wednesday morning in Delaware Chancery Court, a judge has expedited a lawsuit from Valeant (VRX) and Pershing Square's William Ackman against Allergan (AGN), says the Wall Street Journal. Last week Valeant and Ackman sued Allergan to quickly schedule a special meeting to decide on the fate of Allergan's board members, added the Wall Street Journal. Reference Link
August 26, 2014
20:04 EDTVRX, AGNAllergan requests block to Ackman, Valeant votes, announces Special Meeting date
Subscribe for More Information
16:45 EDTVRX, AGNAllergan schedules special meeting on takeover for December 18, WSJ says
Subscribe for More Information
August 22, 2014
19:02 EDTVRX, AGNAllergan confirms Pershing written request, board views Valeant offer inadequate
Subscribe for More Information
18:33 EDTAGN, VRXPershing Square submits requisite requests from Allergan holders to call meeting
Subscribe for More Information
09:33 EDTVRX, AGNValeant to request today special meeting of Allergan holders, CNBC reports
Valeant (VRX) will deliver today a request of 30%-plus of Allergan (AGN) shareholders for a special meeting, CNBC's David Faber reports, citing sources.
06:49 EDTAGN, VRXJudge rejects Allergan inquiry to quicken insider trading case, Reuters says
Subscribe for More Information
06:45 EDTAGN, VRXJudge refuses to prevent special Allergan shareholder meeting, NY Times says
Subscribe for More Information
August 21, 2014
09:42 EDTVRXValeant to sell Precision's assets related to two acne treatments
Subscribe for More Information
August 20, 2014
17:59 EDTAGN, VRXAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTAGN, VRXAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
10:53 EDTVRX, AGNAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTVRX, AGNAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:19 EDTAGNPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:07 EDTVRX, AGNSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
07:04 EDTAGNSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use